Case Control Study
Copyright ©The Author(s) 2024.
World J Clin Cases. Sep 6, 2024; 12(25): 5681-5696
Published online Sep 6, 2024. doi: 10.12998/wjcc.v12.i25.5681
Table 1 Comparison of general clinical data between the sepsis and control groups upon admission
General clinical data
Sepsis group (T)
Control group (C)
T value
P value
Number of cases1010
Age (years)83.10 ± 10.0581.80 ± 9.390.334
Height (cm)163 ± 7.2165.7 ± 9.070.4703
Weight (kg)60.4 ± 8.4566.4 ± 12.50.2247
Systolic blood pressure (kPa)15.95 ± 2.219.64 ± 2.230.0016b
Diastolic pressure (kPa)9.93 ± 1.4410.55 ± 1.760.4046
White blood cell count (109/L)15.1 ± 7.576.15 ± 1.440.0017b
Neutrophil percentage (%)88.11 ± 5.4762.46 ± 5.99< 0.0001d
Platelet count (1012/L)162.3 ± 88.28208.1 ± 41.680.1552
Alanine aminotransferase (U/L)100.94 ± 157.517.51 ± 7.770.1116b
Total bilirubin (μmol/L)24.08 ± 23.5814.85 ± 7.230.2521
Creatinine (μmol/L)130.44 ± 76.6870.84 ± 13.260.0262a
C-reactive protein (mg/L)141 ± 63.091.54 ± 1.15< 0.0001d
Procalcitonin (ng/mL)14.51 ± 16.960.04 ± 0.010.0147a
D-dimer (ng/mL)12.88 ± 27.550.55 ± 0.550.1742a
Table 2 Serum cytokine concentrations in the sepsis and control groups
No.
Cytokine
Sepsis group (T)
Control group (C)
T value
P value
16Ckine_CCL2122115.55 ± 5190.1319744.73 ± 3054.240.26        
2BCA-1_CXCL1369.83 ± 23.9773.73 ± 130.560.93        
3CTACK_CCL27779.84 ± 438.20529.79 ± 199.550.14        
4ENa-78_CXCL52999.36 ± 3172.84939.51 ± 182.150.08        
5EOtaxin-2_CCL2429.51 ± 13.7145.68 ± 20.900.07        
6EOtaxin-3_CCL26104.94 ± 53.7778.45 ± 16.060.19        
7Eotaxin_CCL1176.63 ± 38.2583.49 ± 33.940.69        
8Fractalkine_CX3CL1302.24 ± 163.08118.26 ± 36.840.01        a
9GCP-2_CXCL654.87 ± 39.7436.08 ± 19.610.23        
10GM-CSF27.55 ± 10.4818.01 ± 4.520.03        a
11Gro minus a_CXCL1396.70 ± 471.60217.92 ± 29.770.29        
12Gro-b_CXCL279.72 ± 52.39116.70 ± 76.760.25        
13I-309_Ccl168.07 ± 22.1751.49 ± 8.770.06        
14I-TAC_CXCL1198.14 ± 95.4163.55 ± 17.940.31        
15IFN-g64.52 ± 73.7220.94 ± 6.250.11        
16IL-1084.44 ± 192.836.03 ± 1.300.25        
17IL-16315.86 ± 100.55179.71 ± 64.950.00        c
18IL-1B5.53 ± 3.892.81 ± 0.550.07        
19IL-216.03 ± 25.316.37 ± 7.860.23        
20IL-456.53 ± 18.8153.53 ± 19.020.74        
21IL-63575.78 ± 7581.8514.27 ± 15.510.19        
22IL-8_CXCL8704.18 ± 1779.3713.77 ± 12.440.27        
23IP-10_CXcl10488.38 ± 687.30120.44 ± 50.640.14        
24McP-1_CCL2342.19 ± 565.7660.92 ± 13.310.17        
25McP-2_CCL820.41 ± 14.5212.89 ± 6.680.18        
26McP-3_CCL7181.11 ± 91.81139.20 ± 68.380.29        
27McP-4_CCL1351.51 ± 54.8745.39 ± 15.850.75        
28MDC_CL22205.13 ± 104.45252.88 ± 157.920.46        
29MIF4255.04 ± 3872.224984.17 ± 2222.530.63        
30MIG_CXCL9475.39 ± 420.4796.37 ± 68.500.02        a
31MIP-1a_CL335.18 ± 41.118.40 ± 3.460.08        
32MIP-1delta_CCL152399.60 ± 816.601986.99 ± 836.930.30        
33MIP-3A_CCL20245.17 ± 606.306.20 ± 3.720.27        
34MIP-3b_CCL19411.58 ± 234.76244.49 ± 92.840.07        
35MpIF-1 CCL23748.86 ± 663.34161.30 ± 70.520.03        a
36SCYB16_CXCL16594.64 ± 146.81345.80 ± 198.260.01        b
37Sdf-1a +b_CXCL122201.58 ± 418.861853.09 ± 765.810.25        
38Tarc CL1712.65 ± 14.5721.31 ± 28.890.43        
39TECK_CCL251541.17 ± 697.26931.70 ± 204.770.03        a
40TNF-α222.08 ± 272.3471.74 ± 21.850.13